|
Choices
Steph,
Al's point (that so many trials exclude those with prior Herceptin history) is a major reason why I have trouble with deciding to start Herceptin now, given that I am currently NED. I don't know if the researchers or the companies behind the clinical trials understand how awkward or difficult or cumbersome the clinical trial idea can be for potential participants. Although I have participated in 2 clinical trials thus far and have been a strong advocate for everyone to do what they can to be "part of the solution" to all of the questions about cancer, if the researchers and companies don't see the problem for those of us who are most likely to be interested then I have to question how successful they will be in finding participants as time goes by.
I am probably at less risk than others since I am HER2+++, ER+ and PR+, but even at some risk due to delay I would rather use my situation very carefully to try to add to the knowledge base by documenting the result in some way rather than go off-label. I just hope the researchers and companies see who is out here and make more of an effort to match up with us.
A.A.
|
Threaded Mode